EXACT Sciences (NASDAQ:EXAS) has been given a $65.00 price objective by equities research analysts at Benchmark in a research note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the medical research company’s stock. Benchmark’s target price would suggest a potential upside of 36.33% from the stock’s previous close.

Other analysts also recently issued reports about the company. Zacks Investment Research raised EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 target price for the company in a research report on Tuesday. William Blair reissued a “buy” rating on shares of EXACT Sciences in a research report on Wednesday, January 10th. Bank of America set a $67.00 target price on EXACT Sciences and gave the stock a “buy” rating in a research report on Monday, January 8th. BidaskClub raised EXACT Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. Finally, Leerink Swann reissued an “outperform” rating and issued a $67.00 target price (up from $63.00) on shares of EXACT Sciences in a research report on Monday, November 13th. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $51.64.

Shares of EXACT Sciences (NASDAQ:EXAS) traded down $5.27 on Wednesday, hitting $47.68. The company had a trading volume of 14,210,000 shares, compared to its average volume of 2,150,000. The company has a quick ratio of 9.98, a current ratio of 10.34 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $5,710.00, a P/E ratio of -41.46 and a beta of 0.68. EXACT Sciences has a one year low of $16.95 and a one year high of $63.60.

EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.07. The company had revenue of $72.60 million during the quarter, compared to the consensus estimate of $65.03 million. EXACT Sciences had a negative return on equity of 30.32% and a negative net margin of 60.71%. EXACT Sciences’s revenue was up 158.4% on a year-over-year basis. During the same period last year, the business posted ($0.36) earnings per share. sell-side analysts anticipate that EXACT Sciences will post -1.09 EPS for the current year.

In other news, SVP D Scott Coward sold 1,665 shares of EXACT Sciences stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $52.54, for a total value of $87,479.10. Following the completion of the transaction, the senior vice president now directly owns 37,558 shares in the company, valued at $1,973,297.32. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Graham Peter Lidgard sold 45,775 shares of EXACT Sciences stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $53.60, for a total value of $2,453,540.00. Following the completion of the transaction, the insider now owns 272,819 shares of the company’s stock, valued at $14,623,098.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 735,835 shares of company stock valued at $40,961,278. 4.00% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in EXAS. Krilogy Financial LLC boosted its stake in EXACT Sciences by 1,460.0% during the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock valued at $138,000 after buying an additional 3,650 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in EXACT Sciences by 17.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock valued at $144,000 after buying an additional 600 shares during the period. Crow Point Partners LLC bought a new stake in EXACT Sciences during the fourth quarter valued at $145,000. Oppenheimer Asset Management Inc. boosted its stake in EXACT Sciences by 2,925.7% during the third quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock valued at $150,000 after buying an additional 3,072 shares during the period. Finally, SG Americas Securities LLC bought a new stake in EXACT Sciences during the third quarter valued at $183,000. Institutional investors own 82.39% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “EXACT Sciences (EXAS) PT Set at $65.00 by Benchmark” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2018/01/17/exact-sciences-exas-pt-set-at-65-00-by-benchmark.html.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.